Transplant
Offering pre–and post–transplant diagnostics for the best match
We provide life-changing results for a transplant recipient by offering a comprehensive portfolio of pre-and post-transplant diagnostics for outcome-focused transplant teams. Laboratories use our products to help determine the best match for a solid organ or bone marrow transplant recipient, and to monitor for possible post-transplant rejection. By providing clinicians with accurate test results, we can help advance the practice of transplant medicine.
Supporting diagnostics standardization worldwide
In the last 50 years, transplantation has become a successful clinical practice worldwide. However, there remains little standardization between laboratories across the globe in terms of testing workflows and diagnostic tools to ensure the best compatibility between a patient and a donor. Our products include the highest quality molecular and antibody-based assays and data-driven software solutions for highly specialized Human Leukocyte Antigens (HLA) testing conducted in transplant, registry, and research laboratories.
Helping clinicians make the best donor match for patients
HLA laboratories depend on our high–quality assays for confidence in delivering life-changing results. Our highly technical team of transplant specialists provide a consultative approach to customer support. We are proud to partner with key opinion leaders across the globe and industry partners who provide greater insights into innovation pathways to drive further improvements in the field of transplant diagnostics.
Transplant
Acquisition, integration and innovation
Two key focus areas in 2024 were the integration of commercial operations and systems, and we also targeted our efforts on retaining key talent, with positive results, and expect to finalize remaining integration activities in the coming year.
We completed the acquisition of Omixon, a privately held company based in Budapest, Hungary, focused on the development and commercialization of Next Generation Sequencing (NGS) technologies, in October . We believe the transaction will create significant opportunities for our customers and let us unlock the full potential of both organizations through further investments in product lines, commercial operations, and internal resources. This acquisition will result in broader assay portfolios, new product innovation, and enhanced customer support. These will be key areas of focus in 2025.
We continue to make progress in the commercialization of novel assays targeted to improve the match between a patient and donor. We filed regulatory submission for MatchX, our next generation software for our LIFECODES product portfolio. We are also focused on the commercialization efforts for NanoTYPE, an HLA typing assay using third-generation sequencing technology from Oxford Nanopore Technologies (ONT) which was added to our portfolio through the Omixon acquisition. NanoTYPE is the first HLA sequencing assay to receive EU-IVDR approval and we believe it will be a transformational technology for many transplant laboratories.
In October, we announced the real estate acquisition of our facilities in Waukesha, WI, housing our Transplant Technology Center. Our ninety-four employees who support our LIFECODES product line here call this site home, and for us it is an investment in the community as a long-time business partner. The acquisition also signals our ongoing commitment to invest in the rapidly growing field of Transplant Diagnostics. By owning the building in Waukesha, we have more flexibility to make investments at the site in support of our strategic plan to increase production capacity as we grow our market share.
Dominique Petitgenet
Chief Operating Officer
Transfusion and Transplant
2024 business highlights
Our people in Transplant
Elizabeth Kubiszewski Senior Manager, Production,TransplantI work at Werfen because it gives me a sense of purpose knowing that I’m contributing to something larger than myself.
Even in small ways, every task I perform feels important because it has the potential to improve processes, help people, or lead to positive change. It feels rewarding to be part of an organization that’s working toward the improvement of patient care.
USA
Robert Gleichman Technical & Sales Support Specialist, TransplantI joined Werfen from Immucor. My new team was incredibly welcoming, making my transition both seamless and personally fulfilling.
At Werfen, I’ve been able to do what I love while furthering my knowledge, becoming an active part of the HLA community, and expanding my presence in the LATAM region, a territory that holds a special place in my heart. Most importantly, I’ve had the privilege of making a positive impact on people’s lives through Werfen’s strong focus on patient care.
LATAM
Our products: Powering Patient Care
LIFECODES®
Single Antigen (LSA + LSA NEXA)
Our enhanced LSA and NEXA assays deliver increased coverage, optimized performance, and improved overall workflow for busy HLA laboratories. The assays demonstrate a lower false positive rate, increasing the ability to find acceptable donors for and providing new beginnings for more transplant patients.
Learn more
LIFECODES®
Non-HLA Antibody Assay
The development of post-transplant antibodies against non-HLA autoantigens is associated with rejection and decreased long-term graft survival. Werfen believes in advancing the field of transplantation with a greater understanding of the role of Non-HLA in transplant rejection. LIFECODES Non-HLA Antibody kit detects IgG antibodies to 60 non-HLA autoantigens. The panel was selected from an exhaustive literature search and protoarray analysis.
Learn more
MIA FORA™
NGS MFlex HLA Typing Kits
MIA FORA reports NGS HLA typing results via a sophisticated software that features three algorithms for highly accurate analysis. With the expanded offering of MIA FORA MFlex XP, high-quality results are now available with expanded coverage, in a simplified, multiplex kit format designed to reduce allele ambiguities, improve workflow and reduce turnaround time.
Learn more
NanoTYPE™
NanoTYPE is an HLA typing assay using third generation sequencing technology from Oxford Nanopore Technologies (ONT). The kit has been designed to be combined with a rapid barcoding library preparation from ONT. The easy workflow, rapid turnaround time, long reads and the absence of capital investment for the sequencer makes it an ideal primary or a complementary NGS technique for transplant laboratories.
Learn more about Transplant
Jobs at Transplant
